Company Profile
Fennec Pharmaceuticals Inc. Stock Price, News & Analysis
- Ticker:
- FENC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
10.84 USD (+3.04%)
Close
Last updated: August 6, 2026
347M USD
Market cap
Why the stock is moving
Following the latest company update, “Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026”, FENC closed up 4.06% at $10.52 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Ototoxicity Prevention Company
Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.
Pediatric Commercial Foundation
PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales organization and the Fennec HEARS patient-services hub.
Expansion into Older Patients
Investigator-sponsored studies are evaluating PEDMARK in adolescent, young adult, and adult patients receiving cisplatin for head and neck, testicular, cervical, and other cancers.
Future catalysts
Clinical data from investigator-sponsored PEDMARK studies in additional age groups and tumor types are expected to define potential expansion opportunities.
Recent news
- 01
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Source: Fennec Pharmaceuticals Inc.
- 02
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Source: Fennec Pharmaceuticals Inc.
- 03
Fennec Announces Results of Annual Meeting
Source: Fennec Pharmaceuticals Inc.
- 04
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Source: Fennec Pharmaceuticals Inc.
- 05
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Fennec Pharmaceuticals Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fennec Pharmaceuticals Inc. (FENC)?
Fennec Pharmaceuticals Inc. (FENC) most recently closed at 10.84 USD, a +3.04% move versus the previous session.
What is the market cap of Fennec Pharmaceuticals Inc. (FENC)?
Fennec Pharmaceuticals Inc. currently has a market capitalization of 347M USD on BioPharmSignal.
What does Fennec Pharmaceuticals Inc. do?
Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales...
On which exchange is FENC stock listed?
Fennec Pharmaceuticals Inc. (FENC) is associated with NASDAQ, United States, Biopharma.
What is Ototoxicity?
Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.
Which conditions is Fennec Pharmaceuticals Inc. targeting with Ototoxicity?
Fennec Pharmaceuticals Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Fennec Pharmaceuticals Inc. describe recent progress with Ototoxicity?
Clinical data from investigator-sponsored PEDMARK studies in additional age groups and tumor types are expected to define potential expansion opportunities.
What is Prevention?
Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.